Kanghongbei: Subsidiary obtains drug registration certificate for valsartan amlodipine tablets

Kangbei announced that its wholly-owned subsidiary Hangzhou Kangbei recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for its telmisartan amlodipine tablets. This drug is a compound preparation of telmisartan and amlodipine, used for treating primary hypertension. As of now, Hangzhou Kangbei has invested approximately 10.18 million yuan in research and development expenses for this drug.